Division of Allergy and Immunology, Department of Pediatrics Icahn School of Medicine at Mount Sinai, New York, NY.
Asian Pac J Allergy Immunol. 2013 Sep;31(3):198-209.
Food allergies continue to be an increasingly common disorder, however, no treatment strategies are currently approved for the routine management of individuals with food allergies. Encouraging results from early open-label studies have sparked great interest in oral and sublingual immunotherapy, and thus several randomized controlled trials have recently been conducted to establish the safety and efficacy of these treatment strategies. The aim of this review is to examine the recent studies for peanut, milk and egg allergies.
Open-label and randomized control trials are discussed.
Studies focusing on peanut, milk and egg allergies are included.
Current evidence indicates that desensitization is possible for the majority of subjects who undergo oral immunotherapy. Clinical improvement has been associated with favorable immunologic changes, including smaller skin prick test wheal sizes and increased allergen-specific IgG4 levels. Adverse reactions are common, however, and thus safety concerns remain. Sublingual immunotherapy thus far has not proven to be as effective as oral immune-therapy.
Oral and sublingual immunotherapy are promising treatments for food allergy. Optimization and standardization of protocols, along with additional assessments of safety are still needed.
食物过敏仍是一种越来越常见的疾病,但目前尚无针对食物过敏患者常规管理的治疗策略获得批准。早期开放标签研究的令人鼓舞的结果激发了人们对口服和舌下免疫疗法的极大兴趣,因此最近进行了几项随机对照试验,以确定这些治疗策略的安全性和有效性。本综述旨在研究花生、牛奶和鸡蛋过敏的最新研究。
讨论了开放标签和随机对照试验。
包括专注于花生、牛奶和鸡蛋过敏的研究。
目前的证据表明,对于接受口服免疫疗法的大多数患者来说,脱敏是可能的。临床改善与有利的免疫学变化相关,包括较小的皮肤点刺试验风团大小和增加的过敏原特异性 IgG4 水平。然而,不良反应很常见,因此安全问题仍然存在。到目前为止,舌下免疫疗法尚未被证明像口服免疫疗法那样有效。
口服和舌下免疫疗法是治疗食物过敏的有前途的方法。仍需要优化和标准化方案,并进一步评估安全性。